The Clinical and Economic Burden of Newly Diagnosed Hereditary Transthyretin (ATTRv) Amyloidosis: A Retrospective Analysis of Claims Data
ConclusionPatients newly diagnosed with ATTRv amyloidosis have substantial healthcare utilization and costs in the first year, primarily the initial months, post-diagnosis. Further research should examine later costs associated with disease progression and end-of-life care.
Source: Neurology and Therapy - Category: Neurology Source Type: research
More News: Amyloidosis | Brain | Cardiology | Cardiovascular | Congestive Heart Failure | Diabetes | Emergency Medicine | Endocrinology | Genetics | Heart | Heart Failure | Heart Transplant | Liver | Liver Transplant | Medicare | Neurology | Study | Transplant Surgery | Transplants | Urology & Nephrology